VF-001 is a new drug that enables and accelerates chronic wound repair by providing cell attachment sites and stimulating cell activity. Consequently, skin cells are able to attach, migrate and increase rapidly to restore the wound healing process.VF-001 is applied to the wound weekly, and fits with standard care for chronic wounds. The wound closes, breaking the cycle of inflammation, and leaving healthy, functional tissue.
Nivolumab is a drug that works by improving the activity of T-cells (a type of white blood cells) and thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab is another drug that works in a different way to also increase the activity of T-cells. Both drugs are given by injection into the veins. It is thought these drugs when used together may be more effective than each drug on its own. If licenced, nivolumab in combination with ipilimumab will offer additional treatment option to prolong the lives of people with head and neck cancers.